Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200445983> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W4200445983 abstract "Abstract Background: Immediate hypersensitivity reactions to COVID-19 vaccines have been postulated to be linked to their excipients, such as polyethylene glycol (PEG) in Pfizer Comirnaty, or polysorbate 80 and ethylenediaminetetracetic acid (EDTA) in AstraZeneca ChAdOx1-S [recombinant] (Vaxzevria). These excipients are potentially found in a range of other products, including injectable and oral medications as well as intravenous radiocontrast media (RCM) and various cosmetic products.Currently patients with proven excipient allergy may be advised to avoid a COVID-19 vaccine containing that excipient and/or potentially cross-reactive excipients. We present two cases of previously confirmed EDTA anaphylaxis, who had negative Vaxzevria vaccine in- vivo testing and subsequently tolerated the vaccine. Case 1: A patient with history of anaphylaxis to RCM and local anaesthetics (LA) had positive intradermal test (IDT) to EDTA nine years earlier. Skin testing to Vaxzeria vaccine (up to 1:10 IDT), Comirnaty vaccine (up to 1:10 IDT) and EDTA 0.3mg/mL IDT were negative. However, following EDTA 3mg/ml IDT, he developed immediate generalised urticaria without anaphylaxis. Basophil activation testing was negative to disodium EDTA, Vaxzevria and Cominarty vaccines. Given the negative in- vitro and in- vivo testing to Vaxzevria vaccine, he proceeded to Vaxzevria immunisation and tolerated both doses. Case 2 : A patient with history of anaphylaxis to RCM had positive skin testing to EDTA and RCM containing EDTA six years earlier. Following referral to COVID19 vaccine clinic, Vaxzevria vaccine (1:10 IDT) and Cominarty vaccine (1:10 IDT) were negative whilst EDTA was positive at 0.3mg/mL IDT. He subsequently tolerated both Vaxzevria vaccinations. Conclusion: Excipient allergy does not necessarily preclude a patient from receiving a vaccine containing that excipient. Allergy testing can help identify excipient-allergic patients who may still tolerate vaccination, which is important in situations where COVID-19 vaccination options are limited." @default.
- W4200445983 created "2021-12-31" @default.
- W4200445983 creator A5012931110 @default.
- W4200445983 creator A5016220895 @default.
- W4200445983 creator A5024478613 @default.
- W4200445983 creator A5036132122 @default.
- W4200445983 creator A5046780897 @default.
- W4200445983 creator A5050901953 @default.
- W4200445983 creator A5051941138 @default.
- W4200445983 creator A5069855052 @default.
- W4200445983 creator A5084767969 @default.
- W4200445983 date "2021-12-29" @default.
- W4200445983 modified "2023-09-30" @default.
- W4200445983 title "AstraZeneca ChAdOx1-S COVID-19 Vaccine Can Be Safely Administered in Patients with EDTA Allergy" @default.
- W4200445983 doi "https://doi.org/10.21203/rs.3.rs-1194579/v1" @default.
- W4200445983 hasPublicationYear "2021" @default.
- W4200445983 type Work @default.
- W4200445983 citedByCount "0" @default.
- W4200445983 crossrefType "posted-content" @default.
- W4200445983 hasAuthorship W4200445983A5012931110 @default.
- W4200445983 hasAuthorship W4200445983A5016220895 @default.
- W4200445983 hasAuthorship W4200445983A5024478613 @default.
- W4200445983 hasAuthorship W4200445983A5036132122 @default.
- W4200445983 hasAuthorship W4200445983A5046780897 @default.
- W4200445983 hasAuthorship W4200445983A5050901953 @default.
- W4200445983 hasAuthorship W4200445983A5051941138 @default.
- W4200445983 hasAuthorship W4200445983A5069855052 @default.
- W4200445983 hasAuthorship W4200445983A5084767969 @default.
- W4200445983 hasBestOaLocation W42004459831 @default.
- W4200445983 hasConcept C178790620 @default.
- W4200445983 hasConcept C185592680 @default.
- W4200445983 hasConcept C203014093 @default.
- W4200445983 hasConcept C207480886 @default.
- W4200445983 hasConcept C2775933838 @default.
- W4200445983 hasConcept C2776964284 @default.
- W4200445983 hasConcept C2777239854 @default.
- W4200445983 hasConcept C71924100 @default.
- W4200445983 hasConcept C98274493 @default.
- W4200445983 hasConceptScore W4200445983C178790620 @default.
- W4200445983 hasConceptScore W4200445983C185592680 @default.
- W4200445983 hasConceptScore W4200445983C203014093 @default.
- W4200445983 hasConceptScore W4200445983C207480886 @default.
- W4200445983 hasConceptScore W4200445983C2775933838 @default.
- W4200445983 hasConceptScore W4200445983C2776964284 @default.
- W4200445983 hasConceptScore W4200445983C2777239854 @default.
- W4200445983 hasConceptScore W4200445983C71924100 @default.
- W4200445983 hasConceptScore W4200445983C98274493 @default.
- W4200445983 hasLocation W42004459831 @default.
- W4200445983 hasLocation W42004459832 @default.
- W4200445983 hasOpenAccess W4200445983 @default.
- W4200445983 hasPrimaryLocation W42004459831 @default.
- W4200445983 hasRelatedWork W1990514993 @default.
- W4200445983 hasRelatedWork W2134817886 @default.
- W4200445983 hasRelatedWork W3080123162 @default.
- W4200445983 hasRelatedWork W3090297235 @default.
- W4200445983 hasRelatedWork W3113114371 @default.
- W4200445983 hasRelatedWork W3126392096 @default.
- W4200445983 hasRelatedWork W3160996067 @default.
- W4200445983 hasRelatedWork W3186316978 @default.
- W4200445983 hasRelatedWork W3216394730 @default.
- W4200445983 hasRelatedWork W4304208555 @default.
- W4200445983 isParatext "false" @default.
- W4200445983 isRetracted "false" @default.
- W4200445983 workType "article" @default.